Bio-Techne Agrees to $73-Per-Share Acquisition by Merck KGaA
Bio-Techne Corporation (TECH) has agreed to be acquired by Merck KGaA for $73 per share in an all-cash deal. The acquisition will see Merck's subsidiary, EMD Holdings NewCo, Inc., merge with Bio-Techne, resulting in the latter becoming a wholly-owned subsidiary of Merck. This move is subject to approval from Bio-Techne shareholders, who are expected to vote on the proposal at a special meeting scheduled for [date] 2026.
The Board of Directors at Bio-Techne has unanimously recommended that shareholders approve and adopt the merger agreement. The deal will see each share of Bio-Techne Common Stock issued and outstanding prior to the effective time of the merger converted into the right to receive $73 in cash, without interest, subject to any required tax withholdings.
The acquisition is a result of Merck's efforts to expand its portfolio through strategic acquisitions. This move reflects the company's commitment to investing in innovative technologies and strengthening its presence in the biotechnology sector.